Shareholders in Guangzheng Eye Hospital GroupLtd (SZSE:002524) Have Lost 77%, as Stock Drops 19% This Past Week
Shareholders in Guangzheng Eye Hospital GroupLtd (SZSE:002524) Have Lost 77%, as Stock Drops 19% This Past Week
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Guangzheng Eye Hospital Group Co.,Ltd. (SZSE:002524); the share price is down a whopping 77% in the last three years. That would certainly shake our confidence in the decision to own the stock. And more recent buyers are having a tough time too, with a drop of 50% in the last year. Furthermore, it's down 31% in about a quarter. That's not much fun for holders.
正如每位投资者所知道的那样,不是每次交易都能达到预期,但是重大损失确实会严重拖累整个投资组合。因此,请为光正眼科集团有限公司(SZSE:002524)的长期股东着想。在过去的三年里,股价下跌了惊人的77%。这肯定会动摇我们持有该股股票的决定。最近的买家也很困难,去年下跌了50%。此外,它在约一个季度内下跌了31%。这对持有者来说并不好玩。
If the past week is anything to go by, investor sentiment for Guangzheng Eye Hospital GroupLtd isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果过去一周是真实的,光正眼科集团有限公司的投资者情绪并不乐观,因此让我们看看基本面和股价之间是否存在不匹配。
Given that Guangzheng Eye Hospital GroupLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
考虑到光正眼科集团有限公司过去十二个月没有盈利,我们将关注营业收入增长,以快速了解其业务发展情况。赤字公司的股东通常希望营业收入有强劲的增长。这是因为如果营业收入增长微不足道,从不盈利,那么很难有信心认为公司的持续性很高。在过去的三年里,光正眼科集团有限公司的营业收入每年下降了2.5%。这并不是投资者通常想看到的。股价下跌21%(每年,逾三年)严厉提醒赤字公司必须增长营业收入。如果该企业要像投资者希望的那样表现,显然需要增加营业收入。不要让股价下跌破坏你的冷静,当你冷静时,你会做出更好的决策。
Over the last three years, Guangzheng Eye Hospital GroupLtd's revenue dropped 2.5% per year. That's not what investors generally want to see. The share price fall of 21% (per year, over three years) is a stern reminder that money-losing companies are expected to grow revenue. This business clearly needs to grow revenues if it is to perform as investors hope. Don't let a share price decline ruin your calm. You make better decisions when you're calm.
过去三年,光正眼科集团有限公司的营业收入每年下降2.5%,这通常不是投资者希望看到的。股价下跌了21%(每年,逾三年)严厉提醒赤字公司必须增长营业收入。如果该企业要像投资者希望的那样表现,显然需要增加营业收入。不要让股价下跌破坏你的冷静,当你冷静时,你会做出更好的决策。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的图片中看到收入和营业收入随时间的变化情况(单击图表可查看精确值)。
If you are thinking of buying or selling Guangzheng Eye Hospital GroupLtd stock, you should check out this FREE detailed report on its balance sheet.
如果您想买卖光正眼科集团有限公司的股票,请查看其资产负债表的免费详细报告。
A Different Perspective
不同的观点
We regret to report that Guangzheng Eye Hospital GroupLtd shareholders are down 50% for the year. Unfortunately, that's worse than the broader market decline of 12%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Guangzheng Eye Hospital GroupLtd , and understanding them should be part of your investment process.
遗憾的是,光正眼科集团有限公司的股东今年下跌了50%。不幸的是,这比整个市场下跌的12%还要糟糕。尽管如此,在下跌的市场中股票被过度卖出的情况是不可避免的。关键是要密切关注基本面的发展。遗憾的是,去年的表现还是让人失望,五年来,股东面临着每年7%的总亏损。我们意识到罗斯柴尔德男爵曾说过投资者应该“在大街上有流血时买入”,但我们提醒投资者首先要确认他们正在购买高质量的企业。我认为长期股价是业务表现的代理,这非常有趣。但要真正获得洞察力,我们还需要考虑其他信息。比如,一直存在的投资风险。我们已经确定了光正眼科集团有限公司的1个警告标志,了解它们应该是您的投资过程的一部分。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜欢与管理层一起购买股票,那么您可能会喜欢这个公司的免费列表。 (提示:其中许多公司不为人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。